Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab and Radiation Therapy in Metastatic MSS Colorectal Cancer
NCT04575922Phase 2Unknown
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2020
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in colorectal cancer (metastatic) (mCRC), sponsored by Massachusetts General Hospital. Status: unknown.
02
Drugs
nivolumabipilimumab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT04575922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04575922.